Movement Alert｜BeOne Medicines Rises 3.17% in Regular Trading, Brukinsa Phase 3 MANGROVE Trial Positive Data Continues to Catalyze

Market Focus07-06

On July 6, BeOne Medicines rose 3.17% in regular trading, trading at HK$188.9/share, with turnover of HK$231 million. The stock continues to be driven by positive clinical data from its flagship BTK inhibitor Brukinsa (zanubrutinib).

On the news front, Brukinsa's Phase 3 MANGROVE trial evaluating a chemotherapy-free regimen as first-line treatment for mantle cell lymphoma achieved its primary endpoint of progression-free survival. The combination of Brukinsa plus rituximab demonstrated a 43% reduction in disease progression or death risk versus standard bendamustine-rituximab (HR=0.57). The company plans to present full results at an upcoming medical congress and pursue global regulatory submissions in the second half of the year.

Meanwhile, the broader biotechnology sector rallied strongly, with Innovent Biologics up 6.21%, Remegen up 6.44%, SKB Bio up 5.61%, 3SBio up 4.45%, and Akeso up 3.71%, providing additional upward momentum through sector linkage.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132656959?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 10:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132656959","market":"hk","top_or_hot":-1,"title":"Movement Alert｜BeOne Medicines Rises 3.17% in Regular Trading, Brukinsa Phase 3 MANGROVE Trial Positive Data Continues to Catalyze","media":"Market Focus","content":"<p><p>On July 6, BeOne Medicines rose 3.17% in regular trading, trading at HK$188.9/share, with turnover of HK$231 million. The stock continues to be driven by positive clinical data from its flagship BTK inhibitor Brukinsa (zanubrutinib).</p><p>On the news front, Brukinsa's Phase 3 MANGROVE trial evaluating a chemotherapy-free regimen as first-line treatment for mantle cell lymphoma achieved its primary endpoint of progression-free survival. The combination of Brukinsa plus rituximab demonstrated a 43% reduction in disease progression or death risk versus standard bendamustine-rituximab (HR=0.57). The company plans to present full results at an upcoming medical congress and pursue global regulatory submissions in the second half of the year.</p><p>Meanwhile, the broader biotechnology sector rallied strongly, with Innovent Biologics up 6.21%, Remegen up 6.44%, SKB Bio up 5.61%, 3SBio up 4.45%, and Akeso up 3.71%, providing additional upward momentum through sector linkage.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BeOne Medicines Rises 3.17% in Regular Trading, Brukinsa Phase 3 MANGROVE Trial Positive Data Continues to Catalyze</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BeOne Medicines Rises 3.17% in Regular Trading, Brukinsa Phase 3 MANGROVE Trial Positive Data Continues to Catalyze\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-06 10:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 6, BeOne Medicines rose 3.17% in regular trading, trading at HK$188.9/share, with turnover of HK$231 million. The stock continues to be driven by positive clinical data from its flagship BTK inhibitor Brukinsa (zanubrutinib).</p><p>On the news front, Brukinsa's Phase 3 MANGROVE trial evaluating a chemotherapy-free regimen as first-line treatment for mantle cell lymphoma achieved its primary endpoint of progression-free survival. The combination of Brukinsa plus rituximab demonstrated a 43% reduction in disease progression or death risk versus standard bendamustine-rituximab (HR=0.57). The company plans to present full results at an upcoming medical congress and pursue global regulatory submissions in the second half of the year.</p><p>Meanwhile, the broader biotechnology sector rallied strongly, with Innovent Biologics up 6.21%, Remegen up 6.44%, SKB Bio up 5.61%, 3SBio up 4.45%, and Akeso up 3.71%, providing additional upward momentum through sector linkage.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1132656959","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132656959","pubTimestamp":1783303618,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 6, BeOne Medicines rose 3.17% in regular trading, trading at HK$188.9/share, with turnover of HK$231 million. The stock continues to be driven by positive clinical data from its flagship BTK...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"动向提示|BeOne Medicines常规交易涨3.17%，Brukinsa 3期红树林试验积极数据持续催化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On July 6, BeOne Medicines rose 3.17% in regular trading, trading at HK$188.9/share, with turnover of HK$231 million. The stock continues to be driven by positive clinical data from its flagship BTK inhibitor Brukinsa (zanubrutinib).On the news front, Brukinsa's Phase 3 MANGROVE trial evaluating a chemotherapy-free regimen as first-line treatment for mantle cell lymphoma achieved its primary endpoint of progression-free survival. The combination of Brukinsa plus rituximab demonstrated a 43% reduction in disease progression or death risk versus standard bendamustine-rituximab (HR=0.57). The company plans to present full results at an upcoming medical congress and pursue global regulatory submissions in the second half of the year.Meanwhile, the broader biotechnology sector rallied strongly, with Innovent Biologics up 6.21%, Remegen up 6.44%, SKB Bio up 5.61%, 3SBio up 4.45%, and Akeso up 3.71%, providing additional upward momentum through sector linkage.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132656959","isCrawlerRequest":true}